Jupiter Medical Center Introduces New Procedure to Treat Common Ailment

Aquablation therapy shown to safely and effectively treat enlarged prostate

March 19, 2024 – Jupiter Medical Center announced today that it will now offer Aquablation therapy for the treatment of lower urinary tract symptoms (LUTS) due to benign prostatic hyperplasia (BPH). BPH, or an enlarged prostate, is a non-cancerous condition where the prostate has grown to be larger than normal. Notably, one in two men ages 51 to 60 have this condition, and typical therapies often include high rates of irreversible side effects. The benefits of using Aquablation to treat this common condition include minimal side effects. 

“We are proud to be among the first hospitals in our region to offer the latest treatment for men with BPH,” said Amit Rastogi, MD, MHCM, President and CEO of Jupiter Medical Center. “At Jupiter Medical Center, we remain at the forefront of health care advancements and robotic technology. Our world-class physicians are committed to achieving the best possible outcomes for our patients.”

Jupiter Medical Center is the only hospital in northern Palm Beach County to offer the state-of-the-art procedure.

Aquablation therapy is performed by the AquaBeam^â Robotic System, the first FDA-cleared, surgical robot utilizing automated tissue resection for the treatment of LUTS due to BPH. Aquablation therapy combines real-time, multi-dimensional imaging, automated robotics, and heat-free waterjet ablation for targeted, controlled, and immediate removal of prostate tissue. 

Combining both cystoscopic visualization and ultrasound imaging, surgeons can create a personalized treatment plan tailored to each patient’s anatomy. Once the map is complete, the robotically controlled water jet ablates the prostate tissue, avoiding critical structures to preserve sexual function and continence. Proven in numerous clinical studies, Aquablation therapy offers predictable and reproducible outcomes, independent of prostate anatomy, prostate size, or surgeon experience. 

“If left untreated, BPH can cause significant health problems, including irreversible bladder or kidney damage, bladder stones and incontinence,” said Patrick Tenbrink, MD, urologic surgeon. “Often, however, men are reluctant to treat the condition due to high rates of irreversible complications, including incontinence, erectile dysfunction or ejaculatory dysfunction. The ability to offer Aquablation to our community will be a significant improvement over current therapies.” 

For more information about Aquablation therapy, visit jupitermed.com, call (561) 263-2234, or follow Jupiter Medical Center on Facebook and Instagram @jupitermedicalcenter or on Twitter @JupiterMedCtr. 

ABOUT JUPITER MEDICAL CENTER
Rated #1 in the region for quality, safety and patient experience, Jupiter Medical Center is the leading destination for world-class health care in Palm Beach County and across the Treasure Coast. Jupiter Medical Center’s state-of-the-art facilities and leading-edge technologies enable its award-winning physicians to provide a comprehensive continuum of inpatient and outpatient health care services. Jupiter Medical Center’s specialty centers of excellence include: comprehensive cancer care, cardiovascular care, orthopedics, neurosciences, and women’s and children’s services. For more information about Jupiter Medical Center, please call 561-263-2234 or visit www.jupitermed.com. 

About PROCEPT BioRobotics Corporation

PROCEPT BioRobotics is a surgical robotics company focused on advancing patient care by developing transformative solutions in urology. PROCEPT develops, manufactures, and sells the AquaBeam Robotic System, an advanced, image-guided, surgical robotic system for use in minimally invasive urologic surgery with an initial focus on treating benign prostatic hyperplasia, or BPH. BPH is the most common prostate disease and impacts approximately 40 million men in the United States. PROCEPT designed Aquablation therapy to deliver effective, safe, and durable outcomes for males suffering from lower urinary tract symptoms, or LUTS, due to BPH that are independent of prostate size and shape or surgeon experience. PROCEPT has developed a significant and growing body of clinical evidence, which includes nine clinical studies and over 100 peer-reviewed publications, supporting the benefits and clinical advantages of Aquablation therapy.